Basal Cell Carcinoma
Basal cell carcinoma (BCC), also known as basal cell cancer or basal cell epithelioma, is a common skin cancer. Learn about BCC diagnosis, ICD-10 codes for basal cell carcinoma, clinical documentation requirements, histology, treatment options, and prognosis. This resource provides information for healthcare professionals, including dermatologists, oncologists, and medical coders, seeking accurate and comprehensive information on basal cell carcinoma.
Most common skin cancer, slow-growing, rarely spreads.
Pearly or waxy bump, sore that bleeds or doesn't heal, brown scar-like lesion.
Sun-exposed areas like face, ears, neck, scalp.
ICD-10 Code Families
Complete code families applicable to C44.91
When to use each related code
| Description | When to use |
|---|---|
| Most common skin cancer, rarely spreads. | Use for malignant neoplasm of basal cells of epidermis. Exclude premalignant lesions. |
| Second most common skin cancer, can spread. | Use for malignant neoplasm of keratinocytes of epidermis. Code severity and location. |
| Precancerous skin lesion, potential for SCC. | Use for epidermal keratinocyte dysplasia, including actinic keratosis. Not for invasive SCC. |
Best-practice checklist
- ✓BCC diagnosis: Document lesion size, location, and morphology.
- ✓Basal cell carcinoma: Note any prior BCC history.
- ✓Code basal cell epithelioma with ICD-10 C44. Document subtype if known.
- ✓Basal cell cancer: Include clinical presentation and differential diagnosis.
- ✓Document treatment plan for basal cell carcinoma, including Mohs surgery or other options.
Common pitfalls to avoid
Missing or incorrect laterality (left, right, unspecified) can lead to claim denials and inaccurate reporting for BCC.
Insufficient documentation of the BCC subtype (e.g., nodular, superficial) impacts reimbursement and quality metrics.
Accurate anatomical site coding is crucial for BCC treatment and staging, influencing payment and epidemiological data.
Best-practice tips
- 01Document BCC size, location, and morphology for accurate ICD-10 coding (C44.-).
- 02Complete excision biopsy for staging and confirmation is crucial for CDI and HCC compliance.
- 03Mohs surgery for high-risk BCC optimizes resource use and improves patient outcomes.
- 04Regular skin exams and patient education on sun protection for early detection and prevention.
- 05Thorough clinical photography aids diagnosis, treatment planning, and HCC risk adjustment.
Step-by-step checklist
- 1
Verify lesion location, size, and morphology (ICD-10 C44.-)
- 2
Confirm histopathological diagnosis via biopsy (SNOMED CT 314789004)
- 3
Assess risk factors: sun exposure, family history (RxNorm 749657)
- 4
Evaluate for perineural invasion or high-risk features (ICD-10 C44.0)
- 5
Document treatment plan and follow-up schedule
Ready-to-paste narrative
Patient presents with a concerning skin lesion consistent with basal cell carcinoma (BCC). The lesion, located on [body location], is characterized by [description of lesion: e.g., pearly papule, rolled border, telangiectasia, ulceration, pigmentation]. Patient reports [symptom onset and duration: e.g., noticing the lesion several months ago, slow growth, occasional bleeding]. Medical history includes [relevant medical history: e.g., sun exposure, family history of skin cancer, previous BCC]. Differential diagnosis includes actinic keratosis, squamous cell carcinoma, seborrheic keratosis, and benign melanocytic nevi. Dermoscopic examination reveals [dermoscopic features: e.g., arborizing vessels, blue-gray ovoid nests, leaf-like structures]. Given the clinical presentation and dermoscopic findings, a presumptive diagnosis of basal cell carcinoma is made. Plan includes [treatment plan: e.g., biopsy for histopathological confirmation, Mohs micrographic surgery, excisional surgery, cryotherapy, electrodessication and curettage, radiation therapy, topical chemotherapy]. Patient education provided regarding BCC prognosis, risk factors including ultraviolet radiation exposure, the importance of regular skin examinations, and sun protection strategies. Follow-up appointment scheduled for [date] to discuss biopsy results and finalize treatment plan. ICD-10 code C44. CPT codes for procedures to be determined based on the chosen treatment modality.
Common questions and answers
What are the most effective dermoscopic features for differentiating superficial basal cell carcinoma from benign inflammatory dermatoses in primary care?+
Differentiating superficial basal cell carcinoma (BCC) from benign inflammatory dermatoses clinically and dermoscopically can be challenging in primary care. While no single feature is pathognomonic, certain dermoscopic structures are highly suggestive of superficial BCC. These include short, fine telangiectasia arranged in a superficial, arborizing pattern, multiple small ulcerations, leaf-like areas, and spoke-wheel areas. Benign inflammatory dermatoses, on the other hand, often present with dotted or linear vessels, and other features such as scales, Wickham's striae, or pigmentary changes depending on the specific dermatosis. Accurate diagnosis requires considering the clinical context, patient history, and dermoscopic findings together. When in doubt, a biopsy is always recommended. Explore how integrating dermoscopy into your primary care practice can improve early BCC detection rates.
How do I manage a patient with recurrent basal cell carcinoma after Mohs micrographic surgery, specifically regarding post-surgical surveillance strategies and the role of adjuvant therapy?+
Managing recurrent basal cell carcinoma (BCC) after Mohs micrographic surgery requires a multi-faceted approach. Post-surgical surveillance should be individualized based on the patient's risk factors, including location and histological subtype of the recurrence, previous recurrence history, and immune status. Close follow-up with regular skin examinations is essential. The frequency of these examinations should be determined by the individual patient's risk profile. Consider implementing a standardized photographic documentation protocol to facilitate monitoring. Adjuvant therapies, such as radiation therapy or topical imiquimod, may be considered in cases with high-risk features or multiple recurrences. The decision to use adjuvant therapy should be made in consultation with a dermatologist or oncologist, carefully weighing the potential benefits against the risks and side effects. Learn more about the latest guidelines for managing recurrent BCC and optimizing patient outcomes.
Beyond standard excision, what are the emerging non-surgical treatment options for low-risk basal cell carcinoma, including their efficacy, patient selection criteria, and potential adverse effects?+
Several non-surgical treatment options are available for low-risk basal cell carcinoma (BCC), offering alternatives to standard excision. These include topical therapies like imiquimod and 5-fluorouracil, photodynamic therapy (PDT), and cryotherapy. These modalities are generally considered for superficial BCCs located in cosmetically sensitive areas or in patients who are not suitable surgical candidates. Efficacy varies depending on the treatment modality and the specific characteristics of the BCC. Patient selection is crucial, with factors such as tumor size, location, subtype, and patient comorbidities playing a role in determining the most appropriate approach. Potential adverse effects range from local skin reactions (e.g., erythema, irritation) with topical treatments to scarring and hypopigmentation with PDT or cryotherapy. Clinicians should carefully evaluate each patient's individual circumstances and discuss the potential benefits and risks of each treatment option to ensure informed decision-making. Consider implementing a shared decision-making approach when discussing treatment options with patients.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.